Ribon’s scientific team has made fundamental discoveries on the function of monoPARPs, which have led to a new understanding of the roles these enzymes play in cellular stress responses and their functions in cellular organization, protein degradation and gene expression. MonoPARPs regulate stress responses by modifying the function of key regulatory proteins with the covalent attachment of ADP-ribose derived from a NAD+ molecule, a reaction called MARylation. This mechanism is so essential to biology that it has evolved in viruses, bacteria and animals as a key regulator of protein function.
Ribon is building upon the early biological insights of its scientific founders and has created an integrated technology platform to interrogate monoPARPs and discover and develop first-in-class, small molecule therapeutics for the treatment of diseases with high unmet need, such as cancer.
Across the 12 different monoPARPs, Ribon’s platform can be applied to investigate a wide range of potential new therapeutic opportunities in a variety of therapeutic areas.